Company Overview

Update
Headquarters:
Cambridge
Funding:
$3.10M
Categories:
Biotechnology

Ario Pharma is focused on the development of drugs for the treatment of respiratory indications.

Description

Update

Ario Pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease.

Current Team (1)

Update

Funding Rounds (1) - $3.10M

Update

Offices/Locations (1)

Update
  • Office

    London Road

    Pampisford

    Cambridge, CB22 3EG

    GBR

Images (1)

Update
  • 78ac6f04b782a23c5250aae7498f2f11